Compare PFLT & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFLT | BIOA |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 805.6M | 757.0M |
| IPO Year | 2010 | N/A |
| Metric | PFLT | BIOA |
|---|---|---|
| Price | $8.90 | $17.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $10.50 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 898.6K | 346.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 14.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.16 | $720.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.68 | $3.79 |
| 52 Week High | $10.88 | $24.00 |
| Indicator | PFLT | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 51.74 |
| Support Level | $8.47 | $15.59 |
| Resistance Level | $9.46 | $18.65 |
| Average True Range (ATR) | 0.19 | 1.25 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 48.10 | 43.39 |
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.